This is a preview of subscription content, log in via an institution to check access.
References
Graham DM, et al. The cost-effectiveness of second-line crizotinib in EML4-ALK rearranged advanced non-small cell lung cancer. 15th World Conference on Lung Cancer : abstr. P3.24-037, 27 Oct 2013.
Montero AJ, et al. Cost-effectiveness analysis of crizotinib in metastatic ALK+ Non-Small Cell Lung Cancer (NSCLC). 15th World Conference on Lung Cancer : abstr. P3.11-048, 27 Oct 2013.
Additional information
* cost-effectiveness ratios
Rights and permissions
About this article
Cite this article
Crizotinib effective but too costly in Canada and the US. PharmacoEcon Outcomes News 693, 5 (2013). https://doi.org/10.1007/s40274-013-0929-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0929-x